Refractory Chronic Cough (CALM-2)
Summary
The purpose of this clinical research study is to look at whether the investigational study drug, BLU-5937, works and how safe it is in adults with refractory chronic cough (RCC).
If you choose to take part, you will be in the study for up to 1.5 years (71 weeks). The study will consist of a 4-week screening period, a 55-week study drug treatment period, a 24-week open-label period, and a 12-week follow-up period.
Eligibility
Eligible ages: 18 to 80
Inclusion criteria:
You might be eligible in this trial if:
1) 18 years of age to 80 years of age
2) You have Refractory Chronic Cough.
Exclusion criteria:
You might not be eligible to participate if:
1) You do not have Refractory Chronic Cough
2) Under the age of 18 or over the age of 80
3) You are pregnant or breastfeeding.
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you would like to learn more about how you can get involved with this trial, please contract our study coordinator, Curtis, at 403-220-2123
Principal investigator:
Stephen Field
Clinical trial:
Yes
REB-ID:
REB25-0455
External links